|
BR0209334A
(pt)
|
2001-05-05 |
2004-06-15 |
Smithkline Beecham Plc |
Aminas n-aroil cìclicas
|
|
GB0115862D0
(en)
*
|
2001-06-28 |
2001-08-22 |
Smithkline Beecham Plc |
Compounds
|
|
GB0124463D0
(en)
|
2001-10-11 |
2001-12-05 |
Smithkline Beecham Plc |
Compounds
|
|
GB0127145D0
(en)
*
|
2001-11-10 |
2002-01-02 |
Smithkline Beecham |
Compounds
|
|
GB0130335D0
(en)
*
|
2001-12-19 |
2002-02-06 |
Smithkline Beecham Plc |
Compounds
|
|
JP4498922B2
(ja)
*
|
2002-07-09 |
2010-07-07 |
アクテリオン ファーマシューティカルズ リミテッド |
７，８，９，１０−テトラヒドロ−６Ｈ−アゼピノ、６，７，８，９−テトラヒドロ−ピリドおよび２，３−ジヒドロ−２Ｈ−ピロロ［２，１−ｂ］−キナゾリノン誘導体
|
|
WO2004026866A1
(en)
*
|
2002-09-18 |
2004-04-01 |
Glaxo Group Limited |
N-aroyl cyclic amines as orexin receptor antagonists
|
|
NZ538749A
(en)
*
|
2002-10-11 |
2006-11-30 |
Actelion Pharmaceuticals Ltd |
Sulfonylamino-acetic acid derivatives and their use as orexin receptor antagonists
|
|
GB0225944D0
(en)
*
|
2002-11-06 |
2002-12-11 |
Glaxo Group Ltd |
Novel compounds
|
|
GB0225938D0
(en)
*
|
2002-11-06 |
2002-12-11 |
Glaxo Group Ltd |
Novel compounds
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
ATE383345T1
(de)
|
2003-04-28 |
2008-01-15 |
Actelion Pharmaceuticals Ltd |
Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
|
|
RU2378257C2
(ru)
|
2004-03-01 |
2010-01-10 |
Актелион Фармасьютиклз Лтд |
Замещенные производные 1,2,3,4-тетрагидроизохинолина
|
|
US20080125403A1
(en)
|
2004-04-02 |
2008-05-29 |
Merck & Co., Inc. |
Method of Treating Men with Metabolic and Anthropometric Disorders
|
|
US20060178307A1
(en)
*
|
2005-01-26 |
2006-08-10 |
The Regents Of The University Of California |
Modulation of NMDA receptor currents via orexin receptor and/or CRF receptor
|
|
US7501395B2
(en)
|
2005-04-25 |
2009-03-10 |
Eisai R & D Management Co., Ltd. |
Method of screening for antianxiety drugs
|
|
WO2006126074A2
(en)
*
|
2005-05-26 |
2006-11-30 |
Orchid Research Laboratories Limited |
Heterocyclic derivatives
|
|
US8604031B2
(en)
*
|
2006-05-18 |
2013-12-10 |
Mannkind Corporation |
Intracellular kinase inhibitors
|
|
EP2049110B1
(en)
|
2006-07-14 |
2014-08-20 |
Merck Sharp & Dohme Corp. |
Bridged diazepan orexin receptor antagonists
|
|
CL2007002809A1
(es)
*
|
2006-09-29 |
2008-04-18 |
Actelion Pharmaceuticals Ltd |
Compuestos derivados de 3-aza biciclo [3.1.0]hexano; y su uso en el tratamiento de enfermedades tales como desordenes psicoticos y de ansiedad, desordenes del sueno, uso y abuso de sustancias psicoactivas, demencia y deterioro de funciones cognitivas
|
|
CN101568533A
(zh)
|
2006-12-01 |
2009-10-28 |
埃科特莱茵药品有限公司 |
3-异芳基(氨基或酰胺基)-1-(联苯或苯基噻唑基)羰基哌啶衍生物食欲素受体抑制剂
|
|
PE20081229A1
(es)
|
2006-12-01 |
2008-08-28 |
Merck & Co Inc |
Antagonistas de receptor de orexina de diazepam sustituido
|
|
AR064561A1
(es)
|
2006-12-28 |
2009-04-08 |
Actelion Pharmaceuticals Ltd |
Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina.
|
|
CL2008000836A1
(es)
*
|
2007-03-26 |
2008-11-07 |
Actelion Pharmaceuticals Ltd |
Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
|
|
WO2008143856A1
(en)
|
2007-05-18 |
2008-11-27 |
Merck & Co., Inc. |
Oxo bridged diazepan orexin receptor antagonists
|
|
US8030495B2
(en)
|
2007-05-23 |
2011-10-04 |
Coleman Paul J |
Cyclopropyl pyrrolidine orexin receptor antagonists
|
|
HRP20120240T1
(hr)
|
2007-05-23 |
2012-04-30 |
Merck Sharp & Dohme Corp. |
Piridil piperidin antagonisti receptora za oreksin
|
|
WO2008151257A2
(en)
|
2007-06-04 |
2008-12-11 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
US8106215B2
(en)
*
|
2007-07-03 |
2012-01-31 |
Actelion Pharmaceuticals Ltd. |
3-aza-bicyclo[3.3.0]octane compounds
|
|
AR067665A1
(es)
|
2007-07-27 |
2009-10-21 |
Actelion Pharmaceuticals Ltd |
Derivados de trans-3- aza-biciclo ( 3.1.0) hexano
|
|
KR20100046047A
(ko)
*
|
2007-07-27 |
2010-05-04 |
액테리온 파마슈티칼 리미티드 |
2-아자-비시클로[3.3.0]옥탄 유도체
|
|
US8288411B2
(en)
|
2007-09-24 |
2012-10-16 |
Actelion Pharmaceuticals Ltd. |
Pyrrolidines and piperidines as orexin receptor antagonists
|
|
AU2009215243A1
(en)
|
2008-02-21 |
2009-08-27 |
Actelion Pharmaceuticals Ltd. |
2-aza-bicyclo[2.2.1]heptane derivatives
|
|
JP2011519849A
(ja)
*
|
2008-04-30 |
2011-07-14 |
アクテリオン ファーマシューティカルズ リミテッド |
ピペリジン及びピロリジン化合物
|
|
ES2627848T3
(es)
|
2008-06-04 |
2017-07-31 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
|
WO2010004507A1
(en)
*
|
2008-07-07 |
2010-01-14 |
Actelion Pharmaceuticals Ltd |
Thiazolidine compounds as orexin receptor antagonists
|
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
|
US8410284B2
(en)
|
2008-10-22 |
2013-04-02 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
|
WO2010051206A1
(en)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
KR20110091581A
(ko)
|
2008-12-02 |
2011-08-11 |
글락소 그룹 리미티드 |
Ｎ-｛［1ｒ,4ｓ,6ｒ-3-(2-피리디닐카르보닐)-3-아자비시클로［4.1.0］헵트-4-일］메틸｝-2-헤테로아릴아민 유도체 및 그의 용도
|
|
GB0823467D0
(en)
|
2008-12-23 |
2009-01-28 |
Glaxo Group Ltd |
Novel Compounds
|
|
CN102459229A
(zh)
|
2009-04-24 |
2012-05-16 |
葛兰素集团有限公司 |
用作食欲肽拮抗剂的3-氮杂二环[4.1.0]庚烷
|
|
US20120149711A1
(en)
|
2009-08-24 |
2012-06-14 |
Glaxo Group Limited |
Piperidine derivatives used as orexin antagonists
|
|
EP2470523A1
(en)
|
2009-08-24 |
2012-07-04 |
Glaxo Group Limited |
5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder
|
|
JP2013520502A
(ja)
|
2010-02-25 |
2013-06-06 |
メルク・シャープ・エンド・ドーム・コーポレイション |
有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
WO2012089607A1
(en)
|
2010-12-28 |
2012-07-05 |
Glaxo Group Limited |
Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
|
|
WO2012089606A1
(en)
|
2010-12-28 |
2012-07-05 |
Glaxo Group Limited |
Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
|
|
CA2826649C
(en)
|
2011-02-25 |
2016-07-26 |
Merck Sharp & Dohme Corp. |
Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
|
|
AR088352A1
(es)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
|
|
US9440982B2
(en)
|
2012-02-07 |
2016-09-13 |
Eolas Therapeutics, Inc. |
Substituted prolines/piperidines as orexin receptor antagonists
|
|
JP6346862B2
(ja)
|
2012-02-07 |
2018-06-20 |
エオラス セラピューティクス， インコーポレイテッド |
オレキシンレセプターアンタゴニストとしての置換プロリン／ピペリジン
|
|
DK2855453T3
(en)
|
2012-06-04 |
2017-02-06 |
Actelion Pharmaceuticals Ltd |
Benzimidazol-proline derivatives
|
|
US20140045746A1
(en)
|
2012-08-02 |
2014-02-13 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
BR112015007516A2
(pt)
|
2012-10-10 |
2017-07-04 |
Actelion Pharmaceuticals Ltd |
antagonistas do receptor de orexina que são derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)- pirrolidin-1-il]-metanona
|
|
JP2016516004A
(ja)
|
2013-02-22 |
2016-06-02 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
抗糖尿病二環式化合物
|
|
CN105051040A
(zh)
|
2013-03-12 |
2015-11-11 |
埃科特莱茵药品有限公司 |
作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物
|
|
WO2014139388A1
(en)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
EP2968439A2
(en)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
|
PL3004138T3
(pl)
|
2013-06-05 |
2024-07-29 |
Bausch Health Ireland Limited |
Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
|
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
CN105793257B
(zh)
|
2013-12-03 |
2018-11-13 |
爱杜西亚药品有限公司 |
苯并咪唑环化合物的晶形及其用途
|
|
UA119151C2
(uk)
|
2013-12-03 |
2019-05-10 |
Ідорсія Фармасьютікалз Лтд |
КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
|
|
SI3077391T1
(sl)
|
2013-12-04 |
2018-11-30 |
Idorsia Pharmaceuticals Ltd |
Uporaba benzimidazol-prolinskih derivatov
|
|
TW201613902A
(en)
|
2014-08-13 |
2016-04-16 |
Eolas Therapeutics Inc |
Difluoropyrrolidines as orexin receptor modulators
|
|
US10894789B2
(en)
|
2016-02-12 |
2021-01-19 |
Astrazeneca Ab |
Halo-substituted piperidines as orexin receptor modulators
|
|
EP3454857A1
(en)
|
2016-05-10 |
2019-03-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
|
|
WO2018106518A1
(en)
|
2016-12-06 |
2018-06-14 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
|
WO2018118670A1
(en)
|
2016-12-20 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
|
WO2020007964A1
(en)
|
2018-07-05 |
2020-01-09 |
Idorsia Pharmaceuticals Ltd |
2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
|
|
WO2020099511A1
(en)
|
2018-11-14 |
2020-05-22 |
Idorsia Pharmaceuticals Ltd |
Benzimidazole-2-methyl-morpholine derivatives
|
|
JP2022534704A
(ja)
|
2019-06-04 |
2022-08-03 |
ヘイガー バイオサイエンシズ，エルエルシー |
オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法
|
|
WO2023218023A1
(en)
|
2022-05-13 |
2023-11-16 |
Idorsia Pharmaceuticals Ltd |
Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives
|
|
GB202311280D0
(en)
*
|
2023-07-21 |
2023-09-06 |
Bial Portela & Ca Sa |
Orexin receptor antagonists
|
|
GB202311281D0
(en)
*
|
2023-07-21 |
2023-09-06 |
Bial Portela & Ca Sa |
Orexin receptor antagonists
|